- Ticker
- ACAD
- Price
- 19.83
- Stock movement down
- -0.08 (-0.40%)
- Company name
- ACADIA Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Markedsverdi
- 3.21B
- Ent verdi
- 3.23B
- Pris/omsetning
- 6.28
- Pris/bok
- 7.54
- Utbytte avkastning
- -
- Utbytte vekst
- -
- Vekst år
- -
- FCF-utbetaling
- -
- Etterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -
- 1 års avkastning
- -15.29%
- 3 års avkastning
- -21.93%
- 5 års avkastning
- -8.11%
- 10 års avkastning
- 12.42%
Sist oppdatert: 2023-02-03
UTBYTTE
ACAD betaler ikke utbytte
VERDSETTELSE
Verdsettelsesforhold
Loading...
Verdsettelsesforhold-data
| Etterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Verdsettelse (Salg/Bokført verdi)
Loading...
Verdsettelse (Salg/Bokført verdi) data
| Pris til omsetning | 6.28 |
| Pris til bok | 7.54 |
| EV i forhold til salg | 6.32 |
ØKONOMI
Per aksje
Loading...
Per aksje-data
| Gjeldende aksje antall | 161.93M |
| EPS (TTM) | -1.34 |
| FCF per aksje (TTM) | -0.70 |
Resultatregnskap
Loading...
Resultatregnskap-data
| Inntekter (TTM) | 511.50M |
| Bruttofortjeneste (TTM) | 501.19M |
| Driftsinntekter (TTM) | -222.19M |
| Netto inntekt (TTM) | -217.34M |
| EPS (TTM) | -1.34 |
| EPS (1 år fremover) | -0.78 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 97.98% |
| Driftsmargin (TTM) | -43.44% |
| Fortjenestemargin (TTM) | -42.49% |
Balanse
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
| Kontanter | 154.84M |
| Netto fordringer | 56.14M |
| Samlede omløpsmidler | 521.55M |
| Goodwill | 0.00 |
| Immaterielle eiendeler | 0.00 |
| Eiendom, anlegg og utstyr | 0.00 |
| Sum eiendeler | 602.49M |
| Leverandørgjeld | 10.01M |
| Kortsiktig/nåværende langsiktig gjeld | 63.00M |
| Sum kortsiktig gjeld | 116.57M |
| Sum gjeld | 176.81M |
| Aksjonærenes egenkapital | 425.69M |
| Netto varige driftsmidler | 425.69M |
Kontantstrøm
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
| Kontantstrøm fra drift (TTM) | -113.30M |
| Kapitalutgifter (TTM) | 1.00K |
| Fri kontantstrøm (TTM) | -113.30M |
| Utbetalt utbytte (TTM) | 0.00 |
Finansielle inntekter
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
| Egenkapitalavkastning | -51.06% |
| Avkastning på eiendeler | -36.07% |
| Avkastning på investert kapital | -49.97% |
| Kontantavkastning på investert kapital | -26.05% |
AKSJEINFORMASJON
Aksjediagram
Loading...
Aksjekurs-data
| Åpning | 19.54 |
| Daglig høy | 20.11 |
| Daglig lav | 19.53 |
| Daglig volum | 1.21M |
| Tidenes høyeste | 57.00 |
| 1 år analytikerestimat | 18.47 |
| Beta | 0.59 |
| EPS (TTM) | -1.34 |
| Utbytte per aksje | - |
| Ex-div dato | - |
| Neste dato for resultatpresentasjon | 27 Feb 2023 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| ACAD | S&P500 | |
| Nåværende prisfall fra toppnotering | -65.21% | -13.68% |
| Høyeste prisfall | -96.29% | -56.47% |
| Dato for høyeste fall | 12 Nov 2010 | 9 Mar 2009 |
| Gj.snittlig fall fra topp | -47.92% | -11.49% |
| Gj.snittlig tid til ny topp | 51 days | 13 days |
| Maks tid til ny topp | 1820 days | 1805 days |
SELSKAPSOPPLYSNINGER
Markedsverdi
3.21B
Markedsverdi kategori
Mid-cap
Beskrivelse
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Ansatte
510
Nettsted
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Stephen R. Davis
Land
USA
By
San Diego
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
SAN DIEGO, January 09, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Doug Williamson as Executive Vice President, Head of Research and Development (R&D). Dr. ...
9. januar 2023
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been...
3. januar 2023
SAN DIEGO, January 03, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the journal Drug Safety published results from a retrospective analysis finding a lower mortality risk in p...
3. januar 2023
Acadia Pharmaceuticals is working to develop novel RNA-based medicines for the treatment of severe and rare genetic diseases of the central nervous system. The On-Balance-Volume (OBV) line has weake...
3. januar 2023
SAN DIEGO, December 21, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:00...
21. desember 2022
SAN DIEGO, November 08, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
8. november 2022
Acadia (ACAD) reports a narrower-than-expected loss in the third quarter of 2022 while revenues fall shy of estimates. Tightens guidance for Nuplazid.
3. november 2022
Acadia (ACAD) delivered earnings and revenue surprises of 5.56% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
2. november 2022
SAN DIEGO, November 02, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2022.
2. november 2022
Acadia Pharmaceuticals (ACAD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
1. november 2022
Neste side